Get started
RocketTickers

Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® L

Long
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  
RocketTickers  
NASDAQ:SUPN   Supernus Pharmaceuticals, Inc.
Beyond Technical Analysis
1
0
beyondta
SUPN: Supernus Pharmaceuticals, Inc.
2018-12-14 16:02:00
Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.